“Translating Genetic Insights Into Treatments for Alzheimer’s Disease”
This month at Precision Medicine Thursday at Venture Café, Drs. Marco Colonna and David Holtzman will discuss genetic risk factors for Alzheimer’s disease and the development of potential therapeutics that target these genes. Dr. Colonna will speak about the role of the TREM2 gene in the development of early onset dementia and Alzheimer’s disease and testing of cytokine IL-34 as a therapeutic target for neurodegenerative diseases while Dr. Holtzman will discuss the Apolipoprotein E (ApoE) gene which is the strongest genetic risk factor for Alzheimer’s disease. He will discuss how ApoE4 strongly increases Alzheimer’s disease risk while ApoE2 decreases risk and has the potential to slow down the progression of cognitive decline due to Alzheimer’s disease.
For more information visit the ICTS Precision Medicine website.
The Institute of Clinical and Translational Sciences (ICTS) Precision Medicine team invites you to an on-going collaboration with Venture Café. These sessions will be hosted on the third Thursday of every month.